Veeda Lifesciences Partners with Mango Sciences to Integrate AI in Clinical Trial Services
The move aims to accelerate recruitment, improve data precision, and broaden patient representation across its global network, particularly in Europe.
Veeda Lifesciences has announced an investment in Boston-based healthcare AI company Mango Sciences to integrate artificial intelligence into its clinical trials services.
The move aims to accelerate recruitment, improve data precision, and broaden patient representation across its global network, particularly in Europe.
Through this partnership, Veeda will leverage Mango Sciences’ proprietary Querent™ platform to automate patient identification and enhance trial execution in oncology. The integration is expected to align with regulatory expectations around diversity and enable more efficient, representative trial designs.
"Our partnership will transform Veeda into an AI-driven oncology drug development organization, meeting the growing demand for diversity in clinical trials, which aligns with the expectations of regulators and pharmaceutical companies. We will be one of only a few CROs focused on Oncology with access to this proprietary technology," said Dr. Mahesh Bhalgat, Group CEO and Managing Director, Veeda Clinical Research Limited.
The collaboration also supports Veeda’s digital transformation efforts, which aim to improve operational efficiency and quality assurance in clinical research. Advanced data analytics will enhance patient matching, trial monitoring, and data management capabilities, potentially reducing trial timelines and costs.
"We are integrating Large Language Models (LLMs) and Generative-AI into Querent™ to drive operational efficiencies and improve real-world evidence, ultimately identifying the right drug for the right patient," stated Dr. Mohit Misra, Founder & CEO of Mango Sciences.
Veeda’s ongoing technological investments, including its earlier acquisition of Health Data Specialists (Heads), have expanded its access to oncology cohorts in India and Europe.
Furthermore, the company aims to strengthen its role as a technology-enabled CRO delivering services to pharmaceutical and biopharmaceutical clients globally.
